All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Patients with acute myeloid leukemia (AML) and myelodysplastic syndromes have very limited curative treatment options; therefore, the development of novel therapeutics remains of high importance for the future. On May 17, 2021, an announcement was made about the first patient dosed in a first-in-human and first-in-class clinical study of FHD-286 for the treatment of relapsed/refractory AML. The dose-escalation trial is evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of FHD-286 administered orally as a monotherapy.
FHD-286 is the first clinical candidate of a new class of inhibitors of the BAF chromatin remodeling complex ATPases BRG1 and BRM proteins, directly targeting the genetically determined dependencies of hematologic malignancies within the chromatin regulatory system. FHD-286 is characterized as a highly potent, allosteric, and selective small-molecule enzymatic inhibitor. In preclinical studies, FHD-286 has shown antitumor activity across a broad range of cancers.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox